TRIM58 is a prognostic biomarker remodeling the tumor microenvironment in KRAS-driven lung adenocarcinoma
- PMID: 33406903
- DOI: 10.2217/fon-2020-0645
TRIM58 is a prognostic biomarker remodeling the tumor microenvironment in KRAS-driven lung adenocarcinoma
Abstract
Aim: To comprehensively analyze the expression profiles of ubiquitin-related genes (URGs) and determine potential biomarkers in KRAS-driven lung adenocarcinoma (LUAD). Materials & methods: Differential expression analyses were performed between KRAS-wild and KRAS-mutant LUAD samples from The Cancer Genome Atlas database, and 34 URGs were screened out. ESTIMATE and CIBERSORT methods were used to calculate the ratio of immune and stromal components. Results & conclusion: TRIM58 was positively correlated with abundances of M2 macrophages and resting mast cells and negatively correlated with follicular helper T-cell abundances in KRAS-driven LUAD. TRIM58 was a potential prognosis-associated indicator for tumor microenvironment modulation and played a key role in TME-specific AS landscapes alterations in KRAS-driven LUAD.
Keywords: KRAS mutation; KRAS-driven LUAD; TME; TRIM58; URGs.
Similar articles
-
Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Int Immunopharmacol. 2021 Sep;98:107807. doi: 10.1016/j.intimp.2021.107807. Epub 2021 Jun 25. Int Immunopharmacol. 2021. PMID: 34175739
-
Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.Int Immunopharmacol. 2020 Jan;78:106077. doi: 10.1016/j.intimp.2019.106077. Epub 2019 Dec 5. Int Immunopharmacol. 2020. PMID: 31812070
-
Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.Int Immunopharmacol. 2021 Sep;98:107734. doi: 10.1016/j.intimp.2021.107734. Epub 2021 Jun 25. Int Immunopharmacol. 2021. PMID: 34175738
-
[Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].Magy Onkol. 2020 Sep 23;64(3):231-244. Epub 2020 Aug 6. Magy Onkol. 2020. PMID: 33196710 Review. Hungarian.
-
Targeting Metabolic Bottlenecks in Lung Cancer.Trends Cancer. 2019 Aug;5(8):457-459. doi: 10.1016/j.trecan.2019.06.001. Epub 2019 Jun 27. Trends Cancer. 2019. PMID: 31421901 Review.
Cited by
-
TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation via UPP.Dis Markers. 2023 Jan 5;2023:5899662. doi: 10.1155/2023/5899662. eCollection 2023. Dis Markers. 2023. PMID: 36644609 Free PMC article.
-
Comprehensive Exploration of M2 Macrophages and Its Related Genes for Predicting Clinical Outcomes and Drug Sensitivity in Lung Squamous Cell Carcinoma.J Oncol. 2022 Sep 14;2022:1163924. doi: 10.1155/2022/1163924. eCollection 2022. J Oncol. 2022. PMID: 36157235 Free PMC article.
-
Integrative analysis and experiments to explore angiogenesis regulators correlated with poor prognosis, immune infiltration and cancer progression in lung adenocarcinoma.J Transl Med. 2021 Aug 21;19(1):361. doi: 10.1186/s12967-021-03031-w. J Transl Med. 2021. PMID: 34419075 Free PMC article.
-
A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer.Front Oncol. 2023 Jan 30;13:1095313. doi: 10.3389/fonc.2023.1095313. eCollection 2023. Front Oncol. 2023. PMID: 36793597 Free PMC article.
-
Development and Validation of a Prognostic Model based on 11 E3-related Genes for Colon Cancer Patients.Curr Pharm Des. 2024;30(12):935-951. doi: 10.2174/0113816128292398240306160051. Curr Pharm Des. 2024. PMID: 38898815
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous